A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect

NCT05486195 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Cognitive Disorders

Interventions

DRUG: SDI-118
DRUG: Placebo

Sponsor

AbbVie

Collaborators

[object Object]
[object Object]